In a recent study published in Discovery of cancerHaldar and colleagues report the first evaluation in humans of a pooled mutant KRAS (Kirsten rat sarcoma viral oncogene homolog) peptide vaccine in individuals at high risk for pancreatic ductal adenocarcinoma (PDAC). Vaccination induced broad and durable KRAS-specific mutant T cell responses in most participants, providing proof of concept for targeting oncogenic driver mutations before the development of invasive pancreatic cancer.1
Twenty participants with a hereditary predisposition to PDAC and a radiographic abnormality of the pancreas received mKRAS-VAX, a pooled mutant KRAS peptide vaccine, at weeks 1, 3, 5, and 13. Eighteen of 20 participants met the predefined immune response criterion, with a median 18.2-fold increase in KRAS-specific mutant T cell responses. All treatment-related adverse events were grade 1 or 2, and longitudinal analyzes in a subset showed that vaccine-induced KRAS-reactive T cell clonotypes could persist for up to 2 years.1
The importance of the study lies not simply in demonstrating that a peptide vaccine can induce T cell responses, but also in the timing of when vaccination is attempted. PDAC develops over many years from precursor lesions, and mutant KRAS is already present in many lesions of pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN). Vaccination at this stage may target precancerous cells before extensive tumor heterogeneity and the profoundly immunosuppressive microenvironment of established PDAC have developed. The clustered approach may also be relevant because precursor lesions may contain different KRAS mutant clones. Unlike prophylactic vaccines against oncogenic viruses, mKRAS-VAX aims to generate T cells against cells that have already acquired a cancer-causing somatic mutation.
Optimal disease context has long been a challenge for cancer vaccines. As monotherapy, vaccination may be more attractive when tumor burden is minimal, whereas metastatic disease will likely require combined strategies. Recent studies on melanoma illustrate this spectrum. In untreated advanced melanoma, the combination of pembrolizumab with an immunomodulatory peptide vaccine targeting IDO and PD-L1 numerically prolonged progression-free survival, although the predefined significance threshold was not reached.2 Among anti-PD-1-naive patients, median progression-free survival was 24.8 versus 11.0 months (HR 0.74, 95% CI 0.56-0.98). In high-risk resected melanomas, individualized neoantigen vaccination combined with pembrolizumab produced durable improvements in recurrence-free and distant metastasis-free survival.3 Importantly, the benefit was also pronounced in patients who were ctDNA negative after surgery, supporting the idea that vaccination may be particularly effective in the setting of very low residual tumor burden. The benefit remained durable at 5 years, and it was subsequently announced that the phase III INTerpath-001 trial had met its endpoints of survival without recurrence and without distant metastases. Haldar and colleagues advance the concept toward intercepting it before invasive cancer develops.
However, under PDAC, timing may only be part of the equation. G12D generated the lowest median increase in T cell response, 8.3-fold, compared to 43.9-fold for G12A, 33.7-fold for G12V, and 21.8-fold for G12R.1 This is notable because G12D is also the most prevalent KRAS mutation in PDAC. In a contemporary clinicogenomic series, G12D accounted for 41% of KRAS mutant PDACs, compared to 32% for G12V and 16% for G12R.4 This apparent paradox raises a question that goes beyond vaccine design. Could the high prevalence of G12D and its relatively low immune recognition be biologically linked? Figure 1 illustrates how allele-specific KRAS immune visibility can influence immune selection, pancreatic tumor evolution, and cancer interception.
Conceptual model linking allele-specific KRAS immune visibility to immune selection, pancreatic cancer interception, and tumor evolution. A KRAS mutations occur early during pancreatic carcinogenesis and are already present in precursor lesions such as pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN). b Individual mutant KRAS variants may differ in immune salience. Haldar and colleagues observed marked differences in vaccine-induced immunogenicity, with G12D exhibiting the weakest T cell response despite being the most prevalent KRAS allele in pancreatic ductal adenocarcinoma (PDAC). c We propose that such allele-specific differences in immune recognition may also influence natural immunosurveillance and immunoediting. Better recognized mutant clones may undergo stronger immune-mediated negative selection, while poorly recognized clones such as G12D may more easily persist and grow. d Reduced immune visibility of G12D could therefore contribute to both its evolutionary enrichment in PDAC and reduced responsiveness to KRAS-directed vaccination. Conversely, vaccination may enhance recognition of KRAS-specific mutant T cells and provide the opportunity to intercept cancer before invasive disease develops. Created with BioRender.com
This interpretation is supported by unpublished observations from our group. We detected pre-existing T cell reactivity against common KRAS mutant variants in PDAC patients and healthy donors, with particularly limited recognition of G12D. Notably, several patients with G12D mutant PDAC exhibited substantial responses against other mutant KRAS peptides while showing significantly lower recognition of G12D itself. These observations argue against overall impairment of T cell responsiveness as the sole explanation and suggest that relatively weak recognition of G12D may extend beyond vaccine-induced immunity.
These observations raise the possibility that allele-specific differences in immune visibility exist independent of vaccination and could have consequences much earlier during pancreatic tumor evolution. Population-wide genomic analyzes demonstrate that HLA genotype can shape immune selection for oncogenic driver mutations.5 Preferential loss of the restrictive HLA allele was observed for G12V but not for G12D in the HLA-A*11:01 background, consistent with differential immune pressure between KRAS variants.5 A well-recognized mutant allele may undergo greater immune-mediated negative selection during tumorigenesis, whereas an inconspicuous allele may more easily escape immunosurveillance. Reduced G12D recognition could therefore contribute to both reduced vaccine responsiveness and the evolutionary success of G12D mutant pancreatic cells.
This remains a hypothesis and it is unlikely that immune selection is the sole determinant of the distribution of KRAS alleles. Oncogenic fitness, tissue context, environmental exposures, and mutational processes may also contribute to the patterns observed during pancreatic tumor evolution. The Haldar study included only 20 people with a median follow-up of 16.5 months. The ability of vaccine-induced T cells to prevent PDAC will also depend on their persistence and access to precancerous lesions, effective antigen presentation by mutant cells, and the local immune microenvironment. Although no participants developed PDAC during follow-up, the study was not designed or designed to establish cancer preventive efficacy, and the lack of a control group and limited follow-up prevent conclusions about whether vaccination altered the natural history of PDAC development.
An important next step is therefore to determine whether vaccine-induced KRAS-specific T cells enter pancreatic precursor lesions and recognize or eliminate mutant cells. Haldar and colleagues initiated a window of opportunity cohort in patients undergoing resection of high-risk pancreatic lesions, thereby allowing vaccine-induced systemic immunity to be directly linked to biological effects in precancerous pancreatic tissue.1 This could provide an important bridge between circulating T cell responses and the much more difficult demonstration that vaccination prevents invasive PDAC.
Overall, the significance of the Haldar study may go beyond demonstrating the feasibility of KRAS-directed cancer interception. The relationship between KRAS allele prevalence and immune visibility raises the possibility that allele-specific immune recognition may influence not only vaccine responsiveness but also KRAS mutant clones that escape immunosurveillance during pancreatic carcinogenesis. Understanding this relationship may be important both for developing preventative vaccines and for understanding the evolutionary biology of KRAS mutant PDAC.
…
Gn Health
